FindTrial
Sign In

Pathogen Profile in Bronchoalveolar Lavage Fluid of Treatment-Naïve Patients with Inflammatory Myopathy-Associated Interstitial Lung Disease at Initial Diagnosis

Pathogen Profile in Bronchoalveolar Lavage Fluid of Treatment-Naïve Patients with Inflammatory Myopathy-Associated Interstitial Lung Disease at Initial Diagnosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123740
Enrollment
Unknown
Registered
2026-04-29
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD)

Interventions

MDA5- group:None
MDA5+Ro52+group:None
MDA5+Ro52- group:None
MDA5+ group:None

Sponsors

The Affiliated Hospital of Guizhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with IIM who were newly diagnosed and treatment-naïve; 2. High-resolution computed tomography (HRCT) of the chest showing pulmonary inflammatory exudation or interstitial changes; 3. Completion of BALF tNGS testing.

Exclusion criteria

Exclusion criteria: 1. Previous diagnosis with administration of glucocorticoids, immunosuppressants, biological agents, or JAK inhibitors for more than 1 week; 2. Failure to undergo tNGS testing; 3. Patients complicated with other systemic infections.

Design outcomes

Primary

MeasureTime frame
Sequence number and concentration of pathogens detected by BALF tNGS;—

Secondary

MeasureTime frame
Erythrocyte Sedimentation Rate;Chest CT imaging patterns;C-reactive protein, CRP;—

Countries

China

Contacts

Public ContactLei Yang

The Affiliated Hospital of Guizhou Medical University

55562253@qq.com+86 851 8677 1529

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026